(NASDAQ: IMNM) Immunome's forecast annual revenue growth rate of 270.57% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.99%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Immunome's revenue in 2026 is $4,015,000.On average, 15 Wall Street analysts forecast IMNM's revenue for 2026 to be $313,816,842, with the lowest IMNM revenue forecast at $0, and the highest IMNM revenue forecast at $3,163,083,504. On average, 14 Wall Street analysts forecast IMNM's revenue for 2027 to be $6,957,764,456, with the lowest IMNM revenue forecast at $887,883,089, and the highest IMNM revenue forecast at $17,123,459,573.
In 2028, IMNM is forecast to generate $25,393,003,343 in revenue, with the lowest revenue forecast at $8,878,830,890 and the highest revenue forecast at $41,750,890,252.